MedPath

Optimal Value Increase of Egg Products

Not Applicable
Completed
Conditions
Healthy
Inflammation
Aging
Registration Number
NCT04606628
Lead Sponsor
University of Oslo
Brief Summary

The aim of this project is to evaluate daily intake of eggshell membrane taken as supplement (capsule), will reduce markers of inflammation in older people.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
57
Inclusion Criteria

The study will include home-dwelling men and women ≥ 70 years. All subjects have to be in a good enough condition to meet up at the Department of Nutrition, University of Oslo at two occasions during the study period.

Exclusion Criteria
  • CRP >10 mg/L
  • Egg allergy
  • Use of medication affecting inflammation
  • Unstable use of medication or supplements last 3 months
  • Unwilling to keep the physical activity level, habitual dietary intake, tobacco use and weight stable during the study period
  • Severe illness last 3 months
  • Unwilling to perform physical tests
  • Eligibility
  • Diabetes type I or II, HbA1c ≥ 6.5 %

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in plasma levels of inflammatory markersMeasured at baseline and after 4 weeks (end of study)

concentration of TNFalpha

Secondary Outcome Measures
NameTimeMethod
Peripheral blood mononuclear cell (PBMC) gene expressionMeasured at baseline and after 4 weeks

mRNA levels of of genes involved in lipid metabolism and inflammation

Changes in metabolome plasma profileMeasured at baseline and after 4 weeks

concentration of low molecular molecules in blood

Changes in body weightMeasured at baseline and after 4 weeks

Weight (kg) measured by digital scale

Changes in body mass index (BMI)Measured at baseline and after 4 weeks

Measured as body weight in kg/height in meter2 ( kg/m2)

Change in microbiota composition (optional)Measured at baseline and after 4 weeks

bacteria type and diversity

Changes in physical performanceMeasured at baseline and after 4 weeks

Short Physical Performance Battery (SPPB) test (includes balance test, chair test (sit to stand) and walk test)

Changes in body composition - measured by Bioimpedance (BIA)Measured at baseline and after 4 weeks

fat free mass (% and kg), fatt mass (% and in kg)

Changes in markers related to lipid metabolismMeasured at baseline and after 4 weeks

Blood concentrations of e.g. triglycerides, total-, LDL- and HDL- cholesterol, free fatty acids and lipoprotein subclasses

Changes in satiety hormonesMeasured at baseline and after 4 weeks

e.g. concentration of serum ghrelin, amylin, leptin

Change in muscle strengthMeasured at baseline and after 4 weeks

Measured by grip strength

Trial Locations

Locations (1)

University of Oslo

🇳🇴

Oslo, Norway

University of Oslo
🇳🇴Oslo, Norway

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.